AU2017345724B2 - Methods of delivering a neuroprotective polypeptide to the central nervous system - Google Patents

Methods of delivering a neuroprotective polypeptide to the central nervous system Download PDF

Info

Publication number
AU2017345724B2
AU2017345724B2 AU2017345724A AU2017345724A AU2017345724B2 AU 2017345724 B2 AU2017345724 B2 AU 2017345724B2 AU 2017345724 A AU2017345724 A AU 2017345724A AU 2017345724 A AU2017345724 A AU 2017345724A AU 2017345724 B2 AU2017345724 B2 AU 2017345724B2
Authority
AU
Australia
Prior art keywords
ala
gly
ser
glu
exendin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017345724A
Other languages
English (en)
Other versions
AU2017345724A1 (en
Inventor
Nigel H. Greig
Dong Seok Kim
Hee Kyung Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Peptron Inc
US Department of Health and Human Services
Original Assignee
Peptron Inc
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peptron Inc, Government of the United States of America filed Critical Peptron Inc
Publication of AU2017345724A1 publication Critical patent/AU2017345724A1/en
Application granted granted Critical
Publication of AU2017345724B2 publication Critical patent/AU2017345724B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
    • A61M5/142—Pressure infusion, e.g. using pumps
    • A61M5/14212—Pumping with an aspiration and an expulsion action
    • A61M5/14228—Pumping with an aspiration and an expulsion action with linear peristaltic action, i.e. comprising at least three pressurising members or a helical member
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2017345724A 2016-10-20 2017-10-20 Methods of delivering a neuroprotective polypeptide to the central nervous system Active AU2017345724B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662410748P 2016-10-20 2016-10-20
US62/410,748 2016-10-20
PCT/US2017/057606 WO2018075901A1 (en) 2016-10-20 2017-10-20 Methods of delivering a neuroprotective polypeptide to the central nervous system

Publications (2)

Publication Number Publication Date
AU2017345724A1 AU2017345724A1 (en) 2019-06-06
AU2017345724B2 true AU2017345724B2 (en) 2024-04-18

Family

ID=60382598

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017345724A Active AU2017345724B2 (en) 2016-10-20 2017-10-20 Methods of delivering a neuroprotective polypeptide to the central nervous system

Country Status (12)

Country Link
US (2) US11273130B2 (enExample)
EP (2) EP3528836A1 (enExample)
JP (2) JP7626362B2 (enExample)
KR (2) KR102687778B1 (enExample)
CN (1) CN110191717A (enExample)
AU (1) AU2017345724B2 (enExample)
BR (1) BR112019008021A2 (enExample)
CA (1) CA3040906A1 (enExample)
MX (1) MX2019004476A (enExample)
SG (1) SG11201903462UA (enExample)
WO (1) WO2018075901A1 (enExample)
ZA (1) ZA201902486B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201903462UA (en) 2016-10-20 2019-05-30 Peptron Inc Methods of delivering a neuroprotective polypeptide to the central nervous system
EP4005587A4 (en) * 2019-07-29 2023-08-09 Peptron, Inc. PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF LEVODOPA-INDUCED DYSKINESIA OR SUPPRESSION OF THEIR PROGRESSION
BR112022001595A2 (pt) * 2019-07-29 2022-03-22 Peptron Inc Composição farmacêutica para tratamento ou inibição da progressão da discinesia induzida por levodopa
US20230190657A1 (en) * 2020-05-22 2023-06-22 Trustees Of Boston University Methods and compositions for treating a fibrotic disease
CN112014193B (zh) * 2020-07-24 2021-06-15 武汉大学中南医院 一种新的fj染色方法和装置
US11865213B2 (en) * 2021-07-05 2024-01-09 Mapi Pharma Ltd. Semaglutide depot systems and use thereof
CN116392576A (zh) * 2023-05-26 2023-07-07 南通大学 一种gip受体激动剂在制备治疗脊髓损伤修复靶点药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008117927A1 (en) * 2007-03-27 2008-10-02 Peptron Co., Ltd Composition and microsphere for controlled-release of exendin, and method of preparing the same

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US5609885A (en) 1992-09-15 1997-03-11 Alza Corporation Osmotic membrane and delivery device
US6261584B1 (en) 1996-02-02 2001-07-17 Alza Corporation Sustained delivery of an active agent using an implantable system
PL189289B1 (pl) 1996-02-02 2005-07-29 Alza Corp Sposób przygotowania implantowanego układu do dostarczania substancji aktywnej
US6156331A (en) 1996-02-02 2000-12-05 Alza Corporation Sustained delivery of an active agent using an implantable system
US6132420A (en) 1996-02-02 2000-10-17 Alza Corporation Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems
US6395292B2 (en) 1996-02-02 2002-05-28 Alza Corporation Sustained delivery of an active agent using an implantable system
ZA981610B (en) 1997-03-24 1999-08-26 Alza Corp Self adjustable exit port.
MY125849A (en) 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
CA2299425A1 (en) 1997-08-08 1999-02-18 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
PT1032587E (pt) 1997-11-14 2008-04-21 Amylin Pharmaceuticals Inc Novos compostos agonistas de exendina
KR100576583B1 (ko) 1997-12-22 2006-05-04 알자 코포레이션 서방성 약물 송달 장치용 속도 조절막
WO1999033446A1 (en) 1997-12-29 1999-07-08 Alza Corporation Osmotic delivery system with membrane plug retention mechanism
KR100568917B1 (ko) 1997-12-30 2006-04-07 알자 코포레이션 멤브레인 플러그를 갖는 익제 전달장치
CA2356860C (en) 1998-12-31 2006-11-07 Alza Corporation Osmotic delivery system having space efficient piston
EP1328256B1 (en) 1999-12-21 2005-10-19 Alza Corporation Valve for osmotic devices
US7163688B2 (en) 2001-06-22 2007-01-16 Alza Corporation Osmotic implant with membrane and membrane retention means
ATE408414T1 (de) 2001-07-31 2008-10-15 Us Gov Health & Human Serv Glp 1 exendin 4 peptidanaloga und deren verwendungen
CN100453130C (zh) 2002-06-26 2009-01-21 精达制药公司 用于渗透性药物传递系统的最低顺应性和高容积效率的活塞
US7014636B2 (en) 2002-11-21 2006-03-21 Alza Corporation Osmotic delivery device having a two-way valve and a dynamically self-adjusting flow channel
EP1613389B8 (en) 2003-03-31 2008-05-07 Intarcia Therapeutics, Inc. Osmotic pump with means for dissipating internal pressure
US20080318837A1 (en) * 2003-12-26 2008-12-25 Nastech Pharmaceutical Company Inc. Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide
US20050175701A1 (en) 2004-02-10 2005-08-11 Alza Corporation Capillary moderator for osmotic delivery system
US9089636B2 (en) 2004-07-02 2015-07-28 Valeritas, Inc. Methods and devices for delivering GLP-1 and uses thereof
US8168222B2 (en) * 2004-09-07 2012-05-01 Board Of Regents Of The University Of Nebraska Amphiphilic polymer-protein conjugates and methods of use thereof
MX2008014870A (es) 2006-05-30 2009-02-12 Intarcia Therapeutics Inc Modulador de flujo para sistema de suministro osmotico con canal interno de dos piezas.
MX2009001114A (es) 2006-08-09 2009-02-10 Intarcia Therapeutics Inc Sistemas de suministro osmotico y ensambles de piston.
CN104000779A (zh) 2007-04-23 2014-08-27 精达制药公司 促胰岛素释放肽的混悬制剂及其应用
DK2462246T3 (da) 2009-09-28 2017-11-06 Intarcia Therapeutics Inc Hurtig etablering og/eller afslutning af væsentlig steady-state-lægemiddelafgivelse
US9259432B1 (en) * 2011-01-31 2016-02-16 Parminder J. S. Vig Composition and methods for targeted delivery of a therapeutic compound to the brain or spinal cord of a subject for treatment of neurodegenerative diseases
EP2723359A4 (en) * 2011-06-24 2015-03-11 Amylin Pharmaceuticals Llc METHOD FOR THE TREATMENT OF DIABETES WITH THE HELP OF DELAYED RELEASED FORMULATIONS FROM GLP-1 RECEPTOR AGONISTS
JP6226510B2 (ja) 2012-01-27 2017-11-08 キヤノン株式会社 画像処理システム、処理方法及びプログラム
ITMI20130325A1 (it) 2013-03-05 2014-09-06 Telecom Italia Spa Metodo per misurare e monitorare il livello di accesso a dati personali generati da risorse di un dispositivo d'utente
JP2015192425A (ja) 2014-03-28 2015-11-02 富士通株式会社 デマンド収容変更順序決定方法、およびデマンド収容変更順序決定プログラム
US20170035856A1 (en) 2014-04-16 2017-02-09 Shandong Luye Pharmaceutical Co., Ltd. Exenatide-containing composition and preparation method therefor
SG11201903462UA (en) 2016-10-20 2019-05-30 Peptron Inc Methods of delivering a neuroprotective polypeptide to the central nervous system

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008117927A1 (en) * 2007-03-27 2008-10-02 Peptron Co., Ltd Composition and microsphere for controlled-release of exendin, and method of preparing the same

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Li, Yazhou, et al. "Pharmacokinetics of Exenatide in nonhuman primates following its administration in the form of sustained-release PT320 and Bydureon." Scientific Reports 9.1 (2019): 17208. *
PEPTRON, "SR-EXENATIDE FORTHE TREATMENT OF NEURODEGENEDATIVE DISEASES", JPN6021044080, 2014, ISSN: 0004635077 *
THOMAS FOLTYNIE ET AL: "Exenatide as a potential treatment for patients with Parkinson's disease: First steps into the clinic", ALZHEIMER'S & DEMENTIA: THE JOURNAL OF THE ALZHEIMER'SASSOCIATION, vol. 10, no. 1, (2014-02-01), pages S38 - S46 *
U.S. NATIONAL INSTITUTES OF HEALTH: "NCT01971242 on 2015_03_16: ClinicalTrials.gov Archive", 16 March 2015 (2015-03-16), XP055442181, Retrieved from the Internet [retrieved on 20180118] *

Also Published As

Publication number Publication date
RU2019115110A (ru) 2020-11-24
JP2020500163A (ja) 2020-01-09
JP2023065401A (ja) 2023-05-12
KR20210092335A (ko) 2021-07-23
US20220265563A1 (en) 2022-08-25
ZA201902486B (en) 2021-01-27
MX2019004476A (es) 2019-09-23
EP4635569A2 (en) 2025-10-22
CA3040906A1 (en) 2018-04-26
WO2018075901A9 (en) 2018-06-07
KR20190086460A (ko) 2019-07-22
US11771657B2 (en) 2023-10-03
BR112019008021A2 (pt) 2019-07-09
JP7626362B2 (ja) 2025-02-07
SG11201903462UA (en) 2019-05-30
EP3528836A1 (en) 2019-08-28
AU2017345724A1 (en) 2019-06-06
US20200046645A1 (en) 2020-02-13
WO2018075901A1 (en) 2018-04-26
KR102687778B1 (ko) 2024-07-23
US11273130B2 (en) 2022-03-15
CN110191717A (zh) 2019-08-30
RU2019115110A3 (enExample) 2021-03-02
WO2018075901A8 (en) 2019-05-23

Similar Documents

Publication Publication Date Title
US11771657B2 (en) Methods of delivering a neuroprotective polypeptide to the central nervous system
US10941187B2 (en) GLP-1, exendin-4, peptide analogs and uses thereof
RS53814B1 (sr) Eksendin za lečenje šećerne bolesti i smanjenje telesne težine
AU2002317599A1 (en) GLP-1 exendin-4 peptide analogs and uses thereof
JP2005532309A (ja) 脳の健康に効果のあるインスリン関連ペプチド
AU2005323063B2 (en) Use of GLP-1 and agonists thereof to prevent cardiac myocyte apoptosis
RU2790566C2 (ru) Способы доставки нейропротективного полипептида в центральную нервную систему
AU2014277804B2 (en) Glp-1 exendin-4 peptide analogs and uses thereof
US20230263860A1 (en) Methods And Compositions For Treating Stroke
Class et al. Patent application title: GLP-1, EXENDIN-4, PEPTIDE ANALOGS AND USES THEREOF Inventors: Nigel H. Greig (Phoenix, MD, US) Nigel H. Greig (Phoenix, MD, US) Josephine M. Egan (Baltimore, MD, US) Maire Doyle (Baltimore, MD, US) Harold W. Holloway (Middle River, MD, US) Tracy Perry (Baltimore, MD, US)
Greig et al. GLP-1 exendin-4 peptide analogs and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)